Company intelligence
Psychedelic Alpha
The leading independent, data-driven voice in psychedelics.
About Psychedelic Alpha
The definitive resource for analysis of the emergent psychedelic medicine sector. Cut through the noise with exclusive news, interviews, data and opportunities.
Verified activity
Signals from Psychedelic Alpha
13 published signals
Strategy & Corporate Development
Psychedelic Alpha completed the acquisition of Psychedelic Drug Developer AtaiBeckley by Eli Lilly and Company for a total value of up to $3.8 billion.
Reported by Psychedelic Alpha
Research & Knowledge
Psychedelic Alpha published an overview entry exploring anticipating psychedelic REMS programs, further considerations, shared REMS, REMS as competitive strategy, impact on patient access, off-label use, and drug scheduling.
Reported by Psychedelic Alpha
Research & Knowledge
Psychedelic Alpha published a research paper by Dr. Edward Jacobs and Dr. Bryony Insua-Summerhays in The Ethics Corner for The Psychedelic Practitioner's Special Issue on Preparedness.
Reported by Psychedelic Alpha
Legal & Regulatory
Psychedelic Alpha reported that New Zealand’s Medsafe approved two Kiwi psychiatrists to prescribe and administer MDMA for PTSD.
Reported by Psychedelic Alpha
Presence & Recognition
Psychedelic Alpha hosted a chat with Alaina Jaster to kick off the 6th season of the Psychedelic Brain Science podcast.
Reported by Josh Hardman
Research & Knowledge
Psychedelic Alpha learned that the University of Miami has gifted an ibogaine investigational new drug (IND) package to the U.S. government, according to a social media post by President Donald Trump.
Reported by Psychedelic Alpha
Research & Knowledge
Psychedelic Alpha announced the ASCENT-IBO funding opportunity for the ARPA-H Ibogaine Trial.
Reported by Psychedelic Alpha
Research & Knowledge
Psychedelic Alpha published a special issue on Preparedness by Dr. Edward Jacobs and Dr. Bryony Insua-Summerhays in The Ethics Corner for The Psychedelic Practitioner’s Special Issue on Preparedness
Reported by Psychedelic Alpha
Legal & Regulatory
Psychedelic Alpha noted that drug development company Ceruvia has secured polymorph patents covering proprietary pharmaceutical form and manufacturing of BOL-148, an analog of LSD, though it did not use the term in its press release last week.
Reported by Psychedelic Alpha
Research & Knowledge
Psychedelic Alpha published a Psychedelic Alpha Bulletin featuring developments on psychedelic drug development, policy, and access, including the shuttering of an at-home ketamine company and Carey Turnbull pivoting to pursuing polymorph patents.
Reported by Josh Hardman
Research & Knowledge
Psychedelic Alpha published a Psychedelic Alpha Bulletin featuring developments on psychedelic drug development, policy, and access, including how large pharmaceutical companies like Spravato are advertising approved drug products on Google search results.
Reported by Josh Hardman
Research & Knowledge
Psychedelic Alpha published a Psychedelic Alpha Bulletin featuring developments on psychedelic drug development, policy, and access, including Deborah Mash, the researcher behind the ibogaine IND, stating she has no knowledge of the reported gift.
Reported by Josh Hardman
Research & Knowledge
Psychedelic Alpha published a Psychedelic Alpha Bulletin featuring developments on psychedelic drug development, policy, and access, including ARPA-H's ibogaine funding opportunity ASCENT-IBO and President Trump's announcement that an ibogaine IND has been gifted to the federal government by University of Miami.
Reported by Josh Hardman